Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph not_applicable
1
20%
Ph phase_3
2
40%
Ph phase_4
1
20%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
unknown1
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 32 (40.0%)
Phase 41 (20.0%)
N/A1 (20.0%)

Trials by Status

completed240%
unknown120%
recruiting120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingphase_3

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

NCT04602754
completedphase_2

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

NCT05254002
unknownphase_3

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

NCT04603508
completednot_applicable

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

NCT02792400
terminatedphase_4

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

NCT02985242

Clinical Trials (5)

Showing 5 of 5 trials
NCT04602754Phase 3

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Recruiting
NCT05254002Phase 2

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

Completed
NCT04603508Phase 3

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Unknown
NCT02792400Not Applicable

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Completed
NCT02985242Phase 4

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Terminated

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5